Apellis Pharmaceuticals (APLS) Scheduled to Post Earnings on Monday

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) will be posting its quarterly earnings results after the market closes on Monday, August 8th. Analysts expect Apellis Pharmaceuticals to post earnings of ($1.43) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Apellis Pharmaceuticals (NASDAQ:APLSGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $14.38 million during the quarter, compared to analyst estimates of $12.81 million. Apellis Pharmaceuticals had a negative return on equity of 607.37% and a negative net margin of 866.81%. During the same quarter in the previous year, the firm posted ($2.32) earnings per share. On average, analysts expect Apellis Pharmaceuticals to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Apellis Pharmaceuticals Trading Up 3.3 %

Shares of Apellis Pharmaceuticals stock opened at $63.33 on Friday. The stock has a market cap of $6.75 billion, a P/E ratio of -7.89 and a beta of 1.54. The stock’s 50 day simple moving average is $47.76 and its 200-day simple moving average is $46.30. Apellis Pharmaceuticals has a 1-year low of $27.50 and a 1-year high of $67.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.85 and a quick ratio of 8.58.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, SVP Mark Jeffrey Delong sold 5,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of $57.00, for a total transaction of $285,000.00. Following the completion of the transaction, the senior vice president now directly owns 29,250 shares of the company’s stock, valued at approximately $1,667,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, SVP Mark Jeffrey Delong sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $57.00, for a total value of $285,000.00. Following the completion of the sale, the senior vice president now directly owns 29,250 shares of the company’s stock, valued at approximately $1,667,250. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Federico Grossi sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $55.99, for a total transaction of $139,975.00. Following the completion of the sale, the insider now directly owns 107,384 shares of the company’s stock, valued at $6,012,430.16. The disclosure for this sale can be found here. Insiders sold 101,789 shares of company stock valued at $4,748,310 in the last ninety days. Company insiders own 8.00% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently made changes to their positions in APLS. Bank of America Corp DE raised its holdings in shares of Apellis Pharmaceuticals by 38.9% in the 1st quarter. Bank of America Corp DE now owns 381,958 shares of the company’s stock worth $19,406,000 after purchasing an additional 107,052 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Apellis Pharmaceuticals by 179.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 100,299 shares of the company’s stock worth $5,002,000 after purchasing an additional 64,350 shares in the last quarter. Nomura Holdings Inc. raised its holdings in shares of Apellis Pharmaceuticals by 671.4% in the 1st quarter. Nomura Holdings Inc. now owns 104,067 shares of the company’s stock worth $5,720,000 after purchasing an additional 90,576 shares in the last quarter. Point72 Hong Kong Ltd raised its holdings in shares of Apellis Pharmaceuticals by 449.4% in the 1st quarter. Point72 Hong Kong Ltd now owns 4,181 shares of the company’s stock worth $212,000 after purchasing an additional 3,420 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Apellis Pharmaceuticals by 0.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 500,254 shares of the company’s stock worth $25,418,000 after purchasing an additional 2,172 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Credit Suisse Group increased their target price on Apellis Pharmaceuticals to $49.00 in a report on Friday, May 20th. The Goldman Sachs Group decreased their target price on shares of Apellis Pharmaceuticals from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, May 24th. Roth Capital cut shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and set a $40.00 price target for the company. in a report on Wednesday, April 13th. HC Wainwright assumed coverage on shares of Apellis Pharmaceuticals in a report on Tuesday, July 19th. They issued a “buy” rating and a $75.00 target price for the company. Finally, Stifel Nicolaus initiated coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, June 16th. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $70.36.

About Apellis Pharmaceuticals

(Get Rating)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Further Reading

Earnings History for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.